All News

The Food and Drug Administration’s priority review will focus on the combination of plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

A senior cancer survivor shares her experiences with post-cancer finances and offers some advice to others in the same situation.

Patients with cancer experienced higher levels of loneliness, isolation and symptom burden due to social distancing procedures for COVID-19, according to a recent study.

Sociodemographic factors such as race, marital status, health status and age all played a role in understanding which patients and survivors are receiving informal care from a family member or friend during and after treatment.

On social media, CURE® recently asked its readers to share what was the most surprising thing that changed in their life since receiving a cancer diagnosis. Here’s what they shared.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for May 2021.

A survivor of fibrosarcoma shares his journey through treatment and how he learned to build strength and confidence after the ordeal physically changed his face.

A patient describes the connection that she has with a senior research nurse at the institution where she has been enrolled in a clinical trial since 2019.

A patient with multiple myeloma nominates a nurse who is the welcoming face patients sometimes need when going for doctor’s visits.

A radiation oncology nurse takes the time to educate both patients and her clinical team to better manage side effects during therapy.

A mother describes how lonely she feels as the caregiver of an adult child with cancer.

A patient details the compassionate support that she received from an oncology nurse while receiving back-to-back treatments for cancer.

A cancer survivor explains how she applies the meaning of a book quote to life with cancer.

A patient describes a nurse manager he met while receiving treatment who he looked forward to seeing every day despite being busy with her daily duties.

The FDA approved a kinase inhibitor for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other arrangement.

A patient details the peace he felt in the presence of his oncology nurse while receiving treatment for bladder cancer.

A doctor from the department of radiation oncology at Emory’s Clifton Campus describes a nurse at her institution who goes “above and beyond” her call of duty by training her colleagues and making her patients feel comfortable.

A pancreatic cancer survivor explains how gardening helps him feel at peace.

From a cancer survivor walking 3,000 miles for charity to a runner with cancer crossing the finish line with the help of her teammates, here’s what’s happening in the cancer landscape this week.

Researchers observed no difference in overall and progression-free survival in patients with mantle cell lymphoma who started high-intensity treatment at least 90 days after receiving a diagnosis compared with a non-intensive therapy approach.

As the cancer treatment landscape continues to expand, patients and their caregivers should be aware of the various clinical trials currently being conducted — including studies they can possibly join.

Evidence from a phase 3 trial does not support the addition of Tecentriq to a specific chemotherapy regimen with Avastin for patients with newly diagnosed stage 3 or 4 ovarian cancer.

“Understanding and taking action against racial differences in cancer care and clinical trial participation are made more powerful when we listen to patient voices,” writes one patient with breast cancer.

In this episode of the “CURE® Talks Cancer” podcast, Nicole Body discusses her cancer journey and shares how she found the strength to persevere through treatments and accept the difficult truths.

The PET imaging agent targets prostate-specific membrane antigen levels, which can improve the detection of suspected disease spread or recurrence compared with standard approaches.

For patients with early-stage, unfavorable-risk Hodgkin lymphoma, this treatment option may allow for the reduction or elimination of radiotherapy in patients without malignant disease.

The study results, according to the authors, suggest that the combination of folinic acid plus the chemotherapies fluorouracil and oxaliplatin should become the standard-of-care therapy in patients with advanced biliary tract cancer whose disease progressed with cisplatin and gemcitabine.

The effectiveness of the Pfizer-BioNTech COVID-19 vaccine increased significantly among patients with cancer who received a vaccine booster 21 days after receiving the first dose.